International Symposium “Clinical Trials in a Globalised Society -Building an Effective Cancer Clinical Trials System-“
date : 5/25/2010
Together with visiting experts from each country, over one hundred participants joined in active discussions on how each country is creating effective systems for the cancer domain and development of new medicines in the midst of the ongoing international standardization of clinical research and clinical trial systems.
In the Opening Address, British Ambassador David Warren, U.S. Ambassador John V. Roos, Republic of Korea Minister of Economic Affairs Soon-Taik Hwang, and Japan Cancer Society Goodwill Ambassador Dr. Agnes Chan, together with Institute chairman, Dr. Kiyoshi Kurokawa, greeted participants and stressed the importance of cooperation among the countries in order to deliver effective new medicines more quickly and safely.
During the following Plenary Session, each country’s clinical trial system was introduced by, respectively, Dr. Yung-Jue Bang, Vice President of Korea National Enterprise for Clinical Trials (KoNECT), Dr. Edward Trimble, Head of Gynecologic Cancer Therapeutics and Quality of Cancer Care Therapeutics, Clinical Investigations Branch, at the National Cancer Institute, and Professor Jonathan Ledermann of University College London Cancer Institute. Also, Dr. Toshio Miyata, Assistant Director of Research & Development in the Health Policy Bureau at the Ministry of Health, Labour and Welfare spoke on the current situation and future direction in Japan.
Two panel discussions then followed, exploring the themes of “Promoting International Collaboration in Cancer Clinical Trials” and “Collaboration with Patient Groups”, with active debate on how best to attain a system enabling patient-centered clinical trials while also promoting international collaboration.
To conclude the symposium, concrete ideas and proposals for the future were generated through a review of the day’s discussions and comments from participants. Mr. Kan Suzuki, Senior Vice Minister of Education, Culture, Sports, Science and Technology, then closed the event with a speech emphasizing the importance of clinical research and trials as part of the policy of “Life Innovation,” one of the administration’s growth strategies centered on the healthcare field.
With the continued need for both the improvement and globalization of the clinical research and trial systems, it is anticipated that the four countries will collaborate further in sharing best practices and investigating future issues. It is hoped, therefore, that this symposium can serve as a foundation for deepening discussion and common policy implementation.
Top Research & Recommendations Posts
- [Announcement] HGPI Joins Call for “Global Health and Medical Community Unite To Demand End Fossil Fuel Dependency at COP28” (November 1, 2023)
- [Research Paper] “Rethinking Japan’s Health System Sustainability Under the Planetary Health Framework” Published in Health Systems & Reform (November 21, 2023)
- [Research Report] The Public Opinion Survey on Child-Rearing in Modern Japan (Final Report) (March 4, 2022)
- [Policy Recommendations] Furthering the Development of Precision Cancer Medicine —Proposals for Effective Policy Changes Based on Key Characteristics of Precision Medicine in Cancer Treatment— (September 20, 2022)
- [Activity Report] HGPI Submits Requests for the G7 Hiroshima Summit to the G7 Sous-Sherpa (December 23, 2022)
- [Urgent Recommendations] The Kidney Disease Control Promotion Project – Establishing Kidney Disease Control Measures with Patient, Citizen, and Community Engagement and Collaboration: Recommendations for Current Issues and Topics in Kidney Disease Control (May 11, 2022)
- [Case Study] Akari Shigemi “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance” (AMR Alliance Japan, December 22, 2021)
- [Research Report] Survey of Japanese Physicians Regarding Climate Change and Health (December 3, 2023)
- [Recommendations] The Future of Dementia Policy 2022: Deepening Dementia Policies Centered on People Living with Dementia and their Families to Lead Global Society (July 13, 2022)
- [Announcement] HGPI Declares the Ministry of the Environment-led ‘Deco-Katsu Declaration’ and Participation in the ‘Deco-Katsu’ Supporters (October 16, 2023)
[Registration Open] Online Public Symposium “Dementia Risk Reduction: How Society Should Face the Individualization of Risk” (December 12, 2023)
[Registration Open] (Webinar) HGPI Cooperation with Lancet Countdown 2023 Japan Presentation “Climate Change as a Children’s Health Issue: The Latest Lancet Report Sounds the Alarm for Health Commitments” (December 14, 2023)
[Event Report] The 1st Advisory Board Meeting for Patient and Public Involvement (PPI) Support Project “Necessary Steps for Promoting PPI in Policy Making” (October 3, 2023)
[Policy Recommendations] Coming Together to Protect and Foster: Promoting Innovative and Sustainable Planetary Health in the Asia-Pacific Region to Build Resilient Health Systems (November 29, 2023)
[Announcement] HGPI Endorsed “For the Health of People and Planet: Priorities for a Healthy COP28” (November 30, 2023)